Abstract:Pancreatic cancer is a common highly malignant digestive tract tumor. Due to its location and disease characteristics, it presents significant challenges in treatment. The molecular diversity of pancreatic cancer contributes to its heterogeneity, which may key reasons for the poor efficacy of systemic treatments to date. Apart from surgical interventions, adjuvant therapy remains crucial for pancreatic cancer patients. Several studies have indicated that regular adjuvant chemotherapy following surgery can significantly benefit patients. Genetic testing has emerged in recent years as a new auxiliary diagnostic method for pancreatic cancer, guiding postoperative selection of more appropriate treatment drugs. This article focuses on the significance of genetic testing in the selection of therapeutic drugs for pancreatic cancer.